CNK Stock Analysis: Cinemark Holdings | NYSE
Entertainment | NYSE, USA | Market Cap: 3.730m USD | 12M Return: 20.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 76.4M
Qual. Beats: 0
Rev. Trend: 68.5%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cinemark Holdings, Inc. (NYSE: CNK) is a theatrical exhibition company that operates movie theatres across the United States and Latin America. Founded in 1984 and headquartered in Plano, Texas, the company has been publicly traded since its April 2007 IPO.
Classified within the Movies & Entertainment sub-industry of the Communication Services sector, Cinemark operates a capital-intensive business model that generates revenue primarily through box office ticket sales and food and beverage concessions. Its results are closely tied to film release schedules, seasonal attendance patterns, and consumer discretionary spending on out-of-home entertainment.
- Box office recovery hinges on summer blockbuster slate quality
- Latin American operations drive international segment revenue growth
- Concession margins expand as theatrical attendance rebounds post-pandemic
| Net Income: 170.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.29 > 1.0 |
| NWC/Revenue: -9.37% < 20% (prev -7.95%; Δ -1.42% < -1%) |
| CFO/TA 0.11 > 3% & CFO 494.8m > Net Income 170.1m |
| Net Debt (2.83b) to EBITDA (553.0m): 5.13 < 3 |
| Current Ratio: 0.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (114.7m) vs 12m ago -3.94% < -2% |
| Gross Margin: 32.57% > 18% (prev 64.38%; Δ -31.81% > 0.5%) |
| Asset Turnover: 71.28% > 50% (prev 64.31%; Δ 6.97% > 0%) |
| Interest Coverage Ratio: 2.26 > 6 (EBIT TTM 349.0m / Interest Expense TTM 154.4m) |
| A: -0.07 (Total Current Assets 486.7m - Total Current Liabilities 788.1m) / Total Assets 4.35b |
| B: -0.02 (Retained Earnings -81.6m / Total Assets 4.35b) |
| C: 0.08 (EBIT TTM 349.0m / Avg Total Assets 4.51b) |
| D: 0.10 (Book Value of Equity 381.1m / Total Liabilities 3.96b) |
| Altman-Z'' = 0.10 = B |
| DSRI: 1.13 (Receivables 146.0m/121.0m, Revenue 3.22b/3.01b) |
| GMI: 1.98 (GM 64.38% / 32.57%) |
| AQI: 1.68 (AQ_t 0.62 / AQ_t-1 0.37) |
| SGI: 1.07 (Revenue 3.22b / 3.01b) |
| TATA: -0.07 (NI 170.1m - CFO 494.8m) / TA 4.35b) |
| Beneish M = -1.59 (Cap -4..+1) = CCC |
As of July 29, 2026, the stock is trading at USD 33.66 with a total of 2,535,200 shares traded. Over the past week, the price has changed by +5.39%, over one month by +2.94%, over three months by +14.71% and over the past year by +20.78%.
Current recommended Stop Loss: 32.10 (which is 4.6% or 1.3 ATR below the current price).
Cinemark Holdings has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy CNK.
- StrongBuy: 3
- Buy: 4
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 35.2 | 4.5% |
P/E Trailing = 24.2481
P/E Forward = 14.8148
P/S = 1.1706
P/B = 9.647
P/EG = 1.7222
Revenue TTM = 3.22b USD
EBIT TTM = 349.0m USD
EBITDA TTM = 553.0m USD
Long Term Debt = 1.87b USD (from longTermDebt, last quarter)
Short Term Debt = 23.1m USD (from shortTermDebt, last quarter)
Debt = 3.10b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.11b
Net Debt = 2.83b USD (calculated: Debt 3.10b - CCE 261.7m)
Enterprise Value = 6.56b USD (3.73b + Debt 3.10b - CCE 261.7m)
Interest Coverage Ratio = 2.26 (Ebit TTM 349.0m / Interest Expense TTM 154.4m)
EV/FCF = 25.22x (Enterprise Value 6.56b / FCF TTM 260.3m)
FCF Yield = 3.97% (FCF TTM 260.3m / Enterprise Value 6.56b)
FCF Margin = 8.09% (FCF TTM 260.3m / Revenue TTM 3.22b)
Net Margin = 5.29% (Net Income TTM 170.1m / Revenue TTM 3.22b)
Gross Margin = 32.57% ((Revenue TTM 3.22b - Cost of Revenue TTM 2.17b) / Revenue TTM)
Gross Margin QoQ = 20.98% (prev 17.60%)
Tobins Q-Ratio = 1.51 (Enterprise Value 6.56b / Total Assets 4.35b)
Interest Expense / Debt = 4.99% (Interest Expense 154.4m / Debt 3.10b)
Taxrate = 11.70% (23.1m / 197.4m)
NOPAT = 308.2m (EBIT 349.0m * (1 - 11.70%))
Current Ratio = 0.62 (Total Current Assets 486.7m / Total Current Liabilities 788.1m)
Debt / Equity = 8.12 (Debt 3.10b / totalStockholderEquity, last quarter 381.1m)
Debt / EBITDA = 5.13 (Net Debt 2.83b / EBITDA 553.0m)
Debt / FCF = 10.89 (Net Debt 2.83b / FCF TTM 260.3m)
Total Stockholder Equity = 540.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.77% (Net Income 170.1m / Total Assets 4.35b)
RoE = 31.48% (Net Income TTM 170.1m / Total Stockholder Equity 540.4m)
RoCE = 14.49% (EBIT 349.0m / Capital Employed (Equity 540.4m + L.T.Debt 1.87b))
RoIC = 9.01% (NOPAT 308.2m / Invested Capital 3.42b)
WACC = 4.58% (E(3.73b)/V(6.83b) * Re(4.72%) + D(3.10b)/V(6.83b) * Rd(4.99%) * (1-Tc(0.12)))
Discount Rate = 4.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -46.33 | Cagr: -1.70%
[DCF] Terminal Value 77.97% ; FCFF base≈244.3m ; Y1≈280.0m ; Y5≈412.1m
[DCF] Fair Price = 28.83 (EV 6.20b - Net Debt 2.83b = Equity 3.37b / Shares 116.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 68.47 | Revenue CAGR: 3.57% | SUE: 0.60 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.00 | Chg30d=+8.04% | Revisions=+40% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.70 | Chg30d=-12.39% | Revisions=+10% | Analysts=10
EPS current Year (2026-12-31): EPS=2.14 | Chg30d=-0.80% | Revisions=+40% | GrowthEPS=+105.6% | GrowthRev=+11.2%
EPS next Year (2027-12-31): EPS=2.45 | Chg30d=-0.31% | Revisions=+40% | GrowthEPS=+14.4% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: +44% (up=10, down=3)